The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.

Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...

The biotechnology company, Ultragenyx, has reported a successful fourth quarter and full year 2024 financial results ...

Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate ...

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $98.0, a ...

Discover how Ultragenyx achieved 29% revenue growth in 2024, set 2025 guidance at $640M-$670M, and advanced clinical progress toward profitability by 2027.

Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared ...

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $133.4 million in its fourth quarter. On a per-share basis, the Novato, ...